Search

Your search keyword '"Falcoz, Pierre-Emmanuel"' showing total 554 results
Start Over Author "Falcoz, Pierre-Emmanuel" Publication Year Range Last 10 years
554 results on '"Falcoz, Pierre-Emmanuel"'

4. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Author

Stahel, Rolf, Hiltbrunner, Anita, Kammler, Rosita, Marti, Nesa, Ruepp, Barbara, Dafni, Urania, Tsourti, Zoi, Zygoura, Panagiota, Vervita, Katerina, Dimopoulou, Georgia, Andriakopoulou, Charitini, Stavrou, Androniki, Rüschoff, Jan H., Haberecker, Martina, Dettwiler, Susanne, Prutek, Fabiola, Mittmann, Christiane, Opitz, Isabelle, Vrugt, Bart, Friess, Martina, Matter, Alessandra, Spichiger-Häusermann, Chloé, Kirschner, Michaela B., Felley-Bosco, Emanuela, Baas, Paul, Monkhorst, Kim, Nackaerts, Kristiaan, Verbeken, Eric, Weynand, Birgit, Nafteux, Philippe, Moons, Johnny, Peeters, Liesbet, Ampollini, Luca, Tiseo, Marcello, Silini, Enrico Maria, Gnetti, Letizia, Carbognani, Paolo, de Perrot, Marc, Bavaghar-Zaeimi, Fatemeh, Brcic, Luka, Samarzija, Miroslav, Seiwerth, Sven, Jakopovic, Marko, Nadal, Ernest, Cardenal, Felipe, Llatjos, Roger, Lorente, Susana, Syrigos, Konstantinos, Vamvakaris, Ioannis, Tsimpoukis, Sotirios, Boura, Paraskevi, Gray, Steven G., Finn, Stephen P., Nur, Mutaz Mohammed, Baird, Anne-Marie, Barr, Martin P., Cuffe, Sinead, Gately, Kathy, Aerts, Joachim, Thüsen, Jan von der, Bille, Andrea, Passani, Stefano, Brunelli, Alessandro, Curioni-Fontecedro, Alessandra, von der Thüsen, Jan, Kammler, Roswitha, Peters, Solange, Stahel, Rolf A., and Falcoz, Pierre-Emmanuel

Published
2023
Full Text
View/download PDF

9. Circulating cell-free and extracellular vesicles-derived microRNA as prognostic biomarkers in patients with early-stage NSCLC: results from RESTING study.

Author

Petracci, Elisabetta, Pasini, Luigi, Urbini, Milena, Felip, Enriqueta, Stella, Franco, Davoli, Fabio, Salvi, Maurizio, Beau-Faller, Michele, Tebaldi, Michela, Azzali, Irene, Canale, Matteo, Solli, Piergiorgio, Lai, Giulia, Amat, Ramon, Carbonell, Caterina, Falcoz, Pierre-Emmanuel, Martinez-Marti, Alex, Pencreach, Erwan, Delmonte, Angelo, and Crinò, Lucio

Subjects
NON-small-cell lung carcinoma, PROGRESSION-free survival, EXTRACELLULAR vesicles, PROGNOSIS, TUMOR classification
Abstract

Background: Factors to accurately stratify patients with early-stage non-small cell lung cancer (NSCLC) in different prognostic groups are still needed. This study aims to investigate 1) the prognostic potential of circulating cell-free (CF) and extracellular vesicles (EVs)-derived microRNA (miRNAs), and 2) their added value with respect to known prognostic factors (PFs). Methods: The RESTING study is a multicentre prospective observational cohort study on resected stage IA-IIIA patients with NSCLC. The primary end-point was disease-free survival (DFS), and the main analyses were carried out separately for CF- and EV-miRNAs. CF- and EV-miRNAs were isolated from plasma, and miRNA-specific libraries were prepared and sequenced. To reach the study aims, three statistical models were specified: one using the miRNA data only (Model 1); one using both miRNAs and known PFs (age, gender, and pathological stage) (Model 2), and one using the PFs alone (Model 3). Five-fold cross-validation (CV) was used to assess the predictive performance of each. Standard Cox regression and elastic net regularized Cox regression were used. Results: A total of 222 patients were enrolled. The median follow-up time was 26.3 (95% CI 25.4–27.6) months. From Model 1, three CF-miRNAs and 21 EV-miRNAs were associated with DFS. In Model 2, two CF-miRNAs (miR-29c-3p and miR-877-3p) and five EV-miRNAs (miR-181a-2-3p, miR-182-5p, miR-192-5p, miR-532-3p and miR-589-5p) remained associated with DFS. From pathway enrichment analysis, TGF-beta and NOTCH were the most involved pathways. Conclusion: This study identified promising prognostic CF- and EV-miRNAs that could be used as a non-invasive, cost-effective tool to aid clinical decision-making. However, further evaluation of the obtained miRNAs in an external cohort of patients is warranted. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

10. Survival outcomes following urgent lung transplantation in France and the USA.

Author

Roussel, Arnaud, Sage, Edouard, Falcoz, Pierre-Emmanuel, Thomas, Pascal Alexandre, Castier, Yves, Fadel, Elie, Le Pimpec-Barthes, Françoise, Tronc, François, Jougon, Jacques, Lacoste, Philippe, Claustre, Johanna, Brouchet, Laurent, Dorent, Richard, Cantu, Edward, Harhay, Michael, Porcher, Raphaël, and Mordant, Pierre

Subjects
MEDICAL care, SURVIVAL rate, LUNG transplantation, ARTIFICIAL blood circulation, PROPORTIONAL hazards models, ARTIFICIAL respiration, BRONCHIECTASIS, BLOOD group incompatibility
Published
2024
Full Text
View/download PDF

11. Real-world outcomes of lobectomy, segmentectomy and wedge resection for the treatment of stage c-IA lung carcinoma.

Author

Thomas, Pascal Alexandre, Seguin-Givelet, Agathe, Pages, Pierre-Benoît, Alifano, Marco, Brouchet, Laurent, Falcoz, Pierre-Emmanuel, Baste, Jean-Marc, Glorion, Matthieu, Belaroussi, Yaniss, Filaire, Marc, Heyndrickx, Maxime, Loundou, Anderson, Fourdrain, Alex, Dahan, Marcel, Boyer, Laurent, and group, EPITHOR working

Subjects
PROPENSITY score matching, OVERALL survival, THORACIC surgery, TUMOR microenvironment, SURVIVAL rate, LOBECTOMY (Lung surgery)
Abstract

OBJECTIVES To determine safety and survival outcomes associated with lobectomy, segmentectomy and wedge resection for early-stage lung cancer by quiring the French population-based registry EPIdemiology in THORacic surgery (EPITHOR). METHODS Retrospective analysis of 19 452 patients with stage c IA lung carcinoma who underwent lobectomy, segmentectomy or wedge resection between 2016 and 2022 with curative-intent. Main outcome measures were 90-day mortality and 5-year overall survival estimates. Proportional hazards regression and propensity score matching were used to adjust outcomes for key patient, tumour and practice environment factors. RESULTS The treatment distribution was 72.2% for lobectomy, 21.5% for segmentectomy and 6.3% for wedge. Unadjusted 90-day mortality rates were 1.6%, 1.2% and 1.1%, respectively (P  = 0.10). Unadjusted 5-year overall survival estimates were 80%, 78% and 70%, with significant inter-group survival curves differences (P  < 0.0001). Multivariable proportional hazards regression showed that wedge was associated with worse overall survival [adjusted hazard ratio (AHR), 1.23 (95% confidence interval 1.03–1.47); P  = 0.021] compared with lobectomy, while no significant difference was disclosed when comparing segmentectomy to lobectomy (1.08 [0.97–1.20]; P  = 0.162). The three-way propensity score analyses confirmed similar 90-day mortality rate for wedge resection and segmentectomy compared with lobectomy (hazard ratio: 0.43; 95% confidence interval 0.16–1.11; P  = 0.081 and 0.99; 0.48–2.10; P  = 0.998, respectively), but poorer overall survival (1.45; 1.13–1.86; P  = 0.003 and 1.31; 1–1.71; P  = 0.048, respectively). CONCLUSIONS Wedge resection was associated with comparable 90-day mortality but lower overall survival when compared to lobectomy. Overall, all types of sublobar resections may not offer equivalent oncologic effectiveness in real-world settings. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

13. Protective effect of height on long-term survival of resectable lung cancer: a new feature of the lung cancer paradox

Author

Daffré, Elisa, primary, Porcher, Raphaël, additional, Iannelli, Antonio, additional, Prieto, Mathilde, additional, Brouchet, Laurent, additional, Falcoz, Pierre Emmanuel, additional, Le Pimpec Barthes, Françoise, additional, Pages, Pierre Benoit, additional, Thomas, Pascal Alexandre, additional, Dahan, Marcel, additional, and Alifano, Marco, additional

Published
2024
Full Text
View/download PDF

14. Redefining the Risk of Surgery for Clinical Stage IIIA (N2) Non-Small Cell Lung Cancer: A Pooled Analysis of the STS GTSD and ESTS Registry

Author

Arndt, Andrew T., Brunelli, Alessandro, Cicconi, Silvia, Falcoz, Pierre-Emmanuel, Salati, Michele, Kozower, Benjamin, and Liptay, Michael J.

Subjects
Mortality, Lung cancer, Small cell -- Care and treatment, Medical societies -- Health aspects, Medical colleges -- Health aspects, Lung cancer, Non-small cell -- Care and treatment, Health
Abstract

Background Management of clinical stage IIIA-N2 (cIIIA-N2) non-small cell lung cancer (NSCLC) remains controversial. We evaluated treatment strategies and outcomes in cIIIA-N2 NSCLC patients who underwent pulmonary resection in The Society of Thoracic Surgeons General Thoracic Surgery Database (STS GTSD) and the European Society of Thoracic Surgeons (ESTS) Registry. Methods The STS GTSD and ESTS Registry were queried for patients who underwent pulmonary resection for cIIIA-N2 NSCLC between 2012 and 2016. Demographic variables, treatment strategies, and outcome measures were collected and analyzed. Significance of differences was determined using the [chi].sup.2 test for categorical variables and the Wilcoxon rank sum test for continuous variables. Results Pulmonary resection was performed in 4279 cIIIA-N2 NSCLC patients (2928 STS GTSD; 1351 ESTS). Induction therapy was administered to 49%. Lobectomy was performed in 67.1% and pneumonectomy in 13%. Lobectomy was associated with 19.2% major morbidity and 1.6% operative mortality, while pneumonectomy was associated with 34.1% and 5%, respectively. Induction therapy was associated with a higher rate of major morbidity or mortality than upfront surgery (23.2% vs 19.5%, p = 0.004), driven by pneumonectomy (40.7% vs 30.3%, p = 0.012) rather than lobectomy (20.3% vs 18.8%, p = 0.31). Conclusions Pulmonary resection for cIIIA-N2 NSCLC is associated with low rates of operative morbidity and mortality, with lobectomy having lower morbidity and mortality than pneumonectomy. Induction therapy, particularly chemoradiotherapy, is associated with a higher rate of composite morbidity or mortality than upfront surgery in pneumonectomy patients but not lobectomy patients., Author(s): Andrew T. Arndt [sup.8], Alessandro Brunelli [sup.2], Silvia Cicconi [sup.3], Pierre-Emmanuel Falcoz [sup.4], Michele Salati [sup.5], Benjamin Kozower [sup.6], Michael J. Liptay [sup.1], Gaetano Rocco [sup.7], Justin M. Karush [...]

Published
2021
Full Text
View/download PDF

16. Infectious Mediastinitis: A Retrospective Cohort Study.

Author

Lemmet, Thomas, Mazzucotelli, Jean-Philippe, Collange, Olivier, Fath, Léa, Mutter, Didier, Brigand, Cécile, Falcoz, Pierre-Emmanuel, Danion, François, Lefebvre, Nicolas, Bourne-Watrin, Morgane, Gerber, Victor, Hoellinger, Baptiste, Fabacher, Thibaut, Hansmann, Yves, and Ruch, Yvon

Subjects
MEDIASTINITIS, ESOPHAGEAL perforation, COHORT analysis, ORAL microbiology, RETROSPECTIVE studies, UNIVERSITY hospitals
Abstract

Background This study aimed to characterize the demographics, microbiology, management and treatment outcomes of mediastinitis according to the origin of the infection. Methods This retrospective observational study enrolled patients who had mediastinitis diagnosed according to the criteria defined by the Centers for Disease Control and Prevention and were treated in Strasbourg University Hospital, France, between 1 January 2010 and 31 December 2020. Results We investigated 151 cases, including 63 cases of poststernotomy mediastinitis (PSM), 60 cases of mediastinitis due to esophageal perforation (MEP) and 17 cases of descending necrotizing mediastinitis (DNM). The mean patient age (standard deviation) was 63 (14.5) years, and 109 of 151 patients were male. Microbiological documentation varied according to the origin of the infection. When documented, PSM cases were mostly monomicrobial (36 of 53 cases [67.9%]) and involved staphylococci (36 of 53 [67.9%]), whereas MEP and DNM cases were mostly plurimicrobial (38 of 48 [79.2%] and 8 of 12 [66.7%], respectively) and involved digestive or oral flora microorganisms, respectively. The median duration of anti-infective treatment was 41 days (interquartile range, 21–56 days), and 122 of 151 patients (80.8%) benefited from early surgical management. The overall 1-year survival rate was estimated to be 64.8% (95% confidence interval, 56.6%–74.3%), but varied from 80.1% for DNM to 61.5% for MEP. Conclusions Mediastinitis represents a rare yet deadly infection. The present cohort study exhibited the different patterns observed according to the origin of the infection. Greater insight and knowledge on these differences may help guide the management of these complex infections, especially with respect to empirical anti-infective treatments. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

17. Reply to condello

Author

Bertolaccini, Luca, primary, Brunelli, Alessandro, additional, Falcoz, Pierre-Emmanuel, additional, and Szanto, Zalan, additional

Published
2023
Full Text
View/download PDF

18. Video-assisted thoracic surgery or thoracotomy for lung cancer surgery in obese patients? An analysis of the European Society of Thoracic Surgeons database

Author

Guerrera, Francesco, primary, Brunelli, Alessandro, additional, Falcoz, Pierre-Emmanuel, additional, Filosso, Pier Luigi, additional, Szanto, Zalan, additional, Lausi, Paolo Olivo, additional, Filippini, Claudia, additional, Lyberis, Paraskevas, additional, Rosboch, Giulio Luca, additional, and Ruffini, Enrico, additional

Published
2023
Full Text
View/download PDF

20. Healthcare-associated infections in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study.

Author

Nesseler, Nicolas, Mansour, Alexandre, Schmidt, Matthieu, Para, Marylou, Porto, Alizée, Falcoz, Pierre-Emmanuel, Mongardon, Nicolas, Fougerou, Claire, Ross, James T., Beurton, Antoine, Gaide-Chevronnay, Lucie, Guinot, Pierre-Grégoire, Lebreton, Guillaume, Flecher, Erwan, Vincentelli, André, Massart, Nicolas, Fouquet, Olivier, Pierrot, Marc, Chocron, Sidney, and Flicoteaux, Guillaume

Abstract

Background: Both critically ill patients with coronavirus disease 2019 (COVID-19) and patients receiving extracorporeal membrane oxygenation (ECMO) support exhibit a high incidence of healthcare-associated infections (HAI). However, data on incidence, microbiology, resistance patterns, and the impact of HAI on outcomes in patients receiving ECMO for severe COVID-19 remain limited. We aimed to report HAI incidence and microbiology in patients receiving ECMO for severe COVID-19 and to evaluate the impact of ECMO-associated infections (ECMO-AI) on in-hospital mortality. Methods: For this study, we analyzed data from 701 patients included in the ECMOSARS registry which included COVID-19 patients supported by ECMO in France. Results: Among 602 analyzed patients for whom HAI and hospital mortality data were available, 214 (36%) had ECMO-AI, resulting in an incidence rate of 27 ECMO-AI per 1000 ECMO days at risk. Of these, 154 patients had bloodstream infection (BSI) and 117 patients had ventilator-associated pneumonia (VAP). The responsible microorganisms were Enterobacteriaceae (34% for BSI and 48% for VAP), Enterococcus species (25% and 6%, respectively) and non-fermenting Gram-negative bacilli (13% and 20%, respectively). Fungal infections were also observed (10% for BSI and 3% for VAP), as were multidrug-resistant organisms (21% and 15%, respectively). Using a Cox multistate model, ECMO-AI were not found associated with hospital death (HR = 1.00 95% CI [0.79–1.26], p = 0.986). Conclusions: In a nationwide cohort of COVID-19 patients receiving ECMO support, we observed a high incidence of ECMO-AI. ECMO-AI were not found associated with hospital death. Trial registration number NCT04397588 (May 21, 2020). [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

21. Impact of surgical approach on 90-day mortality after lung resection for nonsmall cell lung cancer in high-risk operable patients.

Author

Etienne, Harry, Pagès, Pierre-Benoît, Iquille, Jules, Falcoz, Pierre Emmanuel, Brouchet, Laurent, Berthet, Jean-Philippe, Le Pimpec Barthes, Françoise, Jougon, Jacques, Filaire, Marc, Baste, Jean-Marc, Anne, Valentine, Renaud, Stéphane, D’Annoville, Thomas, Meunier, Jean Pierre, Jayle, Christophe, Dromer, Christian, Seguin-Givelet, Agathe, Legras, Antoine, Rinieri, Philippe, and Jaillard-Thery, Sophie

Published
2024
Full Text
View/download PDF

26. Patient-Derived Tumoroid for the Prediction of Radiotherapy and Chemotherapy Responses in Non-Small-Cell Lung Cancer

Author

Nounsi, Anasse, primary, Seitlinger, Joseph, additional, Ponté, Charlotte, additional, Demiselle, Julien, additional, Idoux-Gillet, Ysia, additional, Pencreach, Erwan, additional, Beau-Faller, Michèle, additional, Lindner, Véronique, additional, Balloul, Jean-Marc, additional, Quemeneur, Eric, additional, Burckel, Hélène, additional, Noël, Georges, additional, Olland, Anne, additional, Fioretti, Florence, additional, Falcoz, Pierre-Emmanuel, additional, Benkirane-Jessel, Nadia, additional, and Hua, Guoqiang, additional

Published
2023
Full Text
View/download PDF

27. European Society of Thoracic Surgeons expert consensus recommendations on technical standards of segmentectomy for primary lung cancer

Author

Brunelli, Alessandro, primary, Decaluwe, Herbert, additional, Gonzalez, Michel, additional, Gossot, Dominique, additional, Petersen, Rene Horsleben, additional, Augustin, Florian, additional, Assouad, Jalal, additional, Baste, Jean Marc, additional, Batirel, Hasan, additional, Falcoz, Pierre Emmanuel, additional, Almanzar, Santiago Figueroa, additional, Furak, Jozsef, additional, Gomez-Hernandez, Maria Teresa, additional, de Antonio, David Gomez, additional, Hansen, Henrik, additional, Jimenez, Marcelo, additional, Koryllos, Aris, additional, Meacci, Elisa, additional, Opitz, Isabelle, additional, Pages, Pierre Benoit, additional, Piwkowski, Cezary, additional, Ruffini, Enrico, additional, Schneiter, Didier, additional, Stupnik, Tomaz, additional, Szanto, Zalan, additional, Thomas, Pascal, additional, Toker, Alper, additional, Tosi, Davide, additional, and Veronesi, Giulia, additional

Published
2023
Full Text
View/download PDF

28. European Epidemiology of Pleural Mesothelioma—Real-Life Data From a Joint Analysis of the Mesoscape Database of the European Thoracic Oncology Platform and the European Society of Thoracic Surgery Mesothelioma Database

Author

Opitz, Isabelle, primary, Bille, Andrea, additional, Dafni, Urania, additional, Nackaerts, Kristiaan, additional, Ampollini, Luca, additional, de Perrot, Marc, additional, Brcic, Luka, additional, Nadal, Ernest, additional, Syrigos, Konstantinos, additional, Gray, Steven G., additional, Aerts, Joachim, additional, Curioni-Fontecedro, Alessandra, additional, Rüschoff, Jan H., additional, Monkhorst, Kim, additional, Weynand, Birgit, additional, Silini, Enrico Maria, additional, Bavaghar-Zaeimi, Fatemeh, additional, Jakopovic, Marko, additional, Llatjos, Roger, additional, Tsimpoukis, Sotirios, additional, Finn, Stephen P., additional, von der Thüsen, Jan, additional, Marti, Nesa, additional, Dimopoulou, Georgia, additional, Kammler, Roswitha, additional, Peters, Solange, additional, Stahel, Rolf A., additional, Falcoz, Pierre-Emmanuel, additional, Brunelli, Alessandro, additional, Baas, Paul, additional, Stahel, Rolf, additional, Hiltbrunner, Anita, additional, Kammler, Rosita, additional, Ruepp, Barbara, additional, Tsourti, Zoi, additional, Zygoura, Panagiota, additional, Vervita, Katerina, additional, Andriakopoulou, Charitini, additional, Stavrou, Androniki, additional, Haberecker, Martina, additional, Dettwiler, Susanne, additional, Prutek, Fabiola, additional, Mittmann, Christiane, additional, Opitz, Isabelle, additional, Vrugt, Bart, additional, Friess, Martina, additional, Matter, Alessandra, additional, Spichiger-Häusermann, Chloé, additional, Kirschner, Michaela B., additional, Felley-Bosco, Emanuela, additional, Verbeken, Eric, additional, Nafteux, Philippe, additional, Moons, Johnny, additional, Peeters, Liesbet, additional, Tiseo, Marcello, additional, Gnetti, Letizia, additional, Carbognani, Paolo, additional, Samarzija, Miroslav, additional, Seiwerth, Sven, additional, Cardenal, Felipe, additional, Lorente, Susana, additional, Vamvakaris, Ioannis, additional, Boura, Paraskevi, additional, Nur, Mutaz Mohammed, additional, Baird, Anne-Marie, additional, Barr, Martin P., additional, Cuffe, Sinead, additional, Gately, Kathy, additional, Thüsen, Jan von der, additional, and Passani, Stefano, additional

Published
2023
Full Text
View/download PDF

33. Bleeding and thrombotic events in patients with severe COVID-19 supported with extracorporeal membrane oxygenation: a nationwide cohort study

Author

Mansour, Alexandre, Flecher, Erwan, Schmidt, Matthieu, Rozec, Bertrand, Gouin-Thibault, Isabelle, Esvan, Maxime, Fougerou, Claire, Levy, Bruno, Porto, Alizée, Ross, James, Para, Marylou, Manganiello, Sabrina, Lebreton, Guillaume, Vincentelli, André, Nesseler, Nicolas, Pierrot, Marc, Chocron, Sidney, Flicoteaux, Guillaume, Mauriat, Philippe, Ouattara, Alexandre, Roze, Hadrien, Huet, Olivier, Fischer, Marc-Olivier, Alessandri, Claire, Bellaïche, Raphel, Constant, Ophélie, de Roux, Quentin, Ly, André, Meffert, Arnaud, Merle, Jean-Claude, Mongardon, Nicolas, Picard, Lucile, Skripkina, Elena, Folliguet, Thierry, Fiore, Antonio, D’ostrevy, Nicolas, Morgan, Marie-Catherine, Guinot, Pierre-Grégoire, Nguyen, Maxime, Gaide-Chevronnay, Lucie, Terzi, Nicolas, Colin, Gwenhaël, Fabre, Olivier, Astaneh, Arash, Issard, Justin, Fadel, Elie, Fabre, Dominique, Girault, Antoine, Guihaire, Julien, Ion, Iolande, Menager, Jean Baptiste, Mitilian, Delphine, Mercier, Olaf, Stephan, François, Thes, Jacques, Jouan, Jerôme, Duburcq, Thibault, Loobuyck, Valentin, Moussa, Mouhammed, Mugnier, Agnes, Rousse, Natacha, Desebbe, Olivier, Fellahi, Jean-Luc, Henaine, Roland, Pozzi, Matteo, Richard, Jean-Christophe, Riad, Zakaria, Guervilly, Christophe, Hraiech, Sami, Papazian, Laurent, Castanier, Matthias, Chanavaz, Charles, Cadoz, Cyril, Gette, Sebastien, Louis, Guillaume, Portocarrero, Erick, Gaudard, Philippe, Brini, Kais, Bischoff, Nicolas, Kimmoun, Antoine, Mattei, Mathieu, Perez, Pierre, Bourdiol, Alexandre, Hourmant, Yannick, Mahé, Pierre-Joachim, Jaquet, Pierre, Lortat-Jacob, Brice, Mordant, Pierre, Nataf, Patrick, Patrier, Juliette, Provenchère, Sophie, Roué, Morgan, Sonneville, Romain, Tran-Dinh, Alexy, Wicky, Paul-Henri, Al Zreibi, Charles, Cholley, Bernard, Guyonvarch, Yannis, Hamada, Sophie, Harrois, Anatole, Matiello, Jordi, Kerforne, Thomas, Lacroix, Corentin, Brechot, Nicolas, Combes, Alain, Chommeloux, Juliette, Constantin, Jean Michel, D’alessandro, Cosimo, Demondion, Pierre, Demoule, Alexandre, Dres, Martin, Fadel, Guillaume, Fartoukh, Muriel, Hekimian, Guillaume, Juvin, Charles, Leprince, Pascal, Levy, David, Luyt, Charles Edouard, Pineton de Chambrun, Marc, Schoell, Thibaut, Fillâtre, Pierre, Massart, Nicolas, Nicolas, Roxane, Jonas, Maud, Vidal, Charles, Allou, Nicolas, Muccio, Salvatore, Di Perna, Dario, Ruggieri, Vito-Giovanni, Mourvillier, Bruno, Anselmi, Amedeo, Bounader, Karl, Launey, Yoann, Lebouvier, Thomas, Parasido, Alessandro, Reizine, Florian, Seguin, Philippe, Besnier, Emmanuel, Carpentier, Dorothée, Clavier, Thomas, Falcoz, Pierre-Emmanuel, Olland, Anne, Villard, Marion, Bounes, Fanny, Labaste, François, Minville, Vincent, Guillon, Antoine, Fedun, Yannick, CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Nantes Université - UFR de Médecine et des Techniques Médicales (Nantes Univ - UFR MEDECINE), Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ)-Nantes Université - pôle Santé, Nantes Université (Nantes Univ)-Nantes Université (Nantes Univ), Hôpital Guillaume-et-René-Laennec [Saint-Herblain], Défaillance Cardiovasculaire Aiguë et Chronique (DCAC), Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lorraine (UL), Service de Réanimation Médicale [CHRU Nancy], Centre Hospitalier Régional Universitaire de Nancy (CHRU Nancy), Hôpital de la Timone [CHU - APHM] (TIMONE), University of California [Davis] (UC Davis), University of California (UC), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, AP-HP - Hôpital Bichat - Claude Bernard [Paris], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Lille, Institut de cardiologie [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Récepteurs Nucléaires, Maladies Métaboliques et Cardiovasculaires - U1011 (RNMCD), Institut Pasteur de Lille, Réseau International des Instituts Pasteur (RIIP)-Réseau International des Instituts Pasteur (RIIP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Lille-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Nutrition, Métabolismes et Cancer (NuMeCan), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), and This work was supported by a grant from the university hospital of Rennes (Appel à projets CFTR2) and by a grant from the French society of thoracic and cardio-vascular surgery (Société française de chirurgie thoracique et cardio-vasculaire, Bourse Marc Laskar).

Subjects
Anticoagulation, [SDV]Life Sciences [q-bio], Bleeding, COVID-19, Thrombosis, ECMO, Critical Care and Intensive Care Medicine
Abstract

International audience; Purpose: To describe bleeding and thrombotic events and their risk factors in patients receiving extracorporeal membrane oxygenation (ECMO) for severe coronavirus disease 2019 (COVID-19) and to evaluate their impact on in-hospital mortality.Methods: The ECMOSARS registry included COVID-19 patients supported by ECMO in France. We analyzed all patients included up to March 31, 2022 without missing data regarding bleeding and thrombotic events. The association of bleeding and thrombotic events with in-hospital mortality and pre-ECMO variables was assessed using multivariable logistic regression models.Results: Among 620 patients supported by ECMO, 29% had only bleeding events, 16% only thrombotic events and 20% both bleeding and thrombosis. Cannulation site (18% of patients), ear nose and throat (12%), pulmonary bleeding (9%) and intracranial hemorrhage (8%) were the most frequent bleeding types. Device-related thrombosis and pulmonary embolism/thrombosis accounted for most of thrombotic events. In-hospital mortality was 55.7%. Bleeding events were associated with in-hospital mortality (adjusted odds ratio (adjOR) = 2.91[1.94-4.4]) but not thrombotic events (adjOR = 1.02[0.68-1.53]). Intracranial hemorrhage was strongly associated with in-hospital mortality (adjOR = 13.5[4.4-41.5]). Ventilation duration before ECMO ≥ 7 days and length of ECMO support were associated with bleeding. Thrombosis-associated factors were fibrinogen ≥ 6 g/L and length of ECMO support.Conclusions: In a nationwide cohort of COVID-19 patients supported by ECMO, bleeding incidence was high and associated with mortality. Intracranial hemorrhage incidence was higher than reported for non-COVID patients and carried the highest risk of death. Thrombotic events were less frequent and not associated with mortality. Length of ECMO support was associated with a higher risk of both bleeding and thrombosis, supporting the development of strategies to minimize ECMO duration.

Published
2022

35. Chest wall disorders

Author

Falcoz, Pierre-Emmanuel, primary, Santelmo, Nicola, additional, Olland, Anne, additional, and Massard, Gilbert, additional

Published
2019
Full Text
View/download PDF

36. Mediastinitis

Author

Falcoz, Pierre-Emmanuel, primary, Santelmo, Nicola, additional, Olland, Anne, additional, and Gilbert, Massard, additional

Published
2019
Full Text
View/download PDF

38. Oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate in lung cancer surgery: a randomized clinical trial

Author

D'Journo, Xavier Benoit, Falcoz, Pierre-Emmanuel, Alifano, Marco, Le Rochais, Jean-Philippe, D'Annoville, Thomas, Massard, Gilbert, and Regnard, Jean Francois

Subjects
Microbiota (Symbiotic organisms) -- Research -- Health aspects, Mortality -- France, Staphylococcus aureus infections -- Research, Lung cancer -- Research, Clinical trials -- Health aspects -- Research, Surgery -- Research -- Health aspects, Health care industry
Abstract

Purpose Respiratory complications are the leading causes of morbidity and mortality after lung cancer surgery. We hypothesized that oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate (CHG) would be an effective method to reduce these complications as reported in cardiac surgery. Methods In this multicenter parallel-group randomized double-blind placebo-controlled trial, we enrolled consecutive adults scheduled for anatomical pulmonary resection for lung cancer. Perioperative decontamination consisted in oropharyngeal rinse solution (0.12% CHG) and nasopharyngeal soap (4% CHG) or a placebo. The primary outcome measure was the proportion of patients requiring postoperative invasive and/or noninvasive mechanical ventilation (MV). Secondary outcome measures included occurrence of respiratory and non-respiratory healthcare-associated infections (HAIs) and outcomes within 90 days. Results Between July 2012 and April 2015, 474 patients were randomized. Of them, 24 had their surgical procedure cancelled or withdrew consent. The remaining 450 patients were included in a modified intention-to-treat analysis: 226 were allocated to CHG and 224 to the placebo. Proportions of patients requiring postoperative MV were not significantly different [CHG 14.2%; placebo 15.2%; relative risks (RRs) 0.93; 95% confidence interval (CI) 0.59-1.45; P = 0.76]. Neither of the proportions of patients with respiratory HAIs were different (CHG 13.7%; placebo 12.9%; RRs 1.06; 95% CI 0.66-1.69; P = 0.81). The CHG group had significantly decreased incidence of bacteremia, surgical-site infection and overall Staphylococcus aureus infections. However, there were no significant between-group differences for hospital stay length, change in tracheal microbiota, postoperative antibiotic utilization and outcomes by day 90. Conclusions CHG decontamination decreased neither MV requirements nor respiratory infections after lung cancer surgery. Additionally, CHG did not change tracheal microbiota or postoperative antibiotic utilization. Trial Registration This study is registered on ClinicalTrials.gov, number NCT01613365., Author(s): Xavier Benoit D'Journo [sup.1] [sup.6], Pierre-Emmanuel Falcoz [sup.2], Marco Alifano [sup.3], Jean-Philippe Le Rochais [sup.4], Thomas D'Annoville [sup.5], Gilbert Massard [sup.2], Jean Francois Regnard [sup.3], Philippe Icard [sup.4], Charles [...]

Published
2018
Full Text
View/download PDF

39. Oropharyngeal and nasopharyngeal decontamination with chlorhexidine gluconate in lung cancer surgery: a randomized clinical trial

Author

D’Journo, Xavier Benoit, Falcoz, Pierre-Emmanuel, Alifano, Marco, Le Rochais, Jean-Philippe, D’Annoville, Thomas, Massard, Gilbert, Regnard, Jean Francois, Icard, Philippe, Marty-Ane, Charles, Trousse, Delphine, Doddoli, Christophe, Orsini, Bastien, Edouard, Sophie, Million, Matthieu, Lesavre, Nathalie, Loundou, Anderson, Baumstarck, Karine, Peyron, Florence, Honoré, Stephane, Dizier, Stéphanie, Charvet, Aude, Leone, Marc, Raoult, Didier, Papazian, Laurent, and Thomas, Pascal Alexandre

Published
2018
Full Text
View/download PDF

40. Prognostic Value of Exon 19 Versus 21 EGFR Mutations Varies According to Disease Stage in Surgically Resected Non-small Cell Lung Cancer Adenocarcinoma

Author

Renaud, Stéphane, Seitlinger, Joseph, Guerrera, Francesco, Reeb, Jérémie, Beau-Faller, Michèle, Voegeli, Anne-Claire, Siat, Joelle, Clément-Duchêne, Christelle, Tiotiu, Angelica, Santelmo, Nicola, Costardi, Lorena, Ruffini, Enrico, Falcoz, Pierre-Emmanuel, Vignaud, Jean-Michel, and Massard, Gilbert

Published
2018
Full Text
View/download PDF

41. Prognostic score and sex-specific nomograms to predict survival in resectable lung cancer: a French nationwide study from the Epithor cohort database

Author

Alifano, Marco, primary, Daffré, Elisa, additional, Brouchet, Laurent, additional, Falcoz, Pierre Emmanuel, additional, Le Pimpec Barthes, Françoise, additional, Pages, Pierre Benoit, additional, Thomas, Pascal Alexandre, additional, Dahan, Marcel, additional, and Porcher, Raphael, additional

Published
2023
Full Text
View/download PDF

43. Veno-Arterial Extracorporeal Membrane Oxygenation for Circulatory Failure in COVID-19 Patients: Insights from the ECMOSARS Registry

Author

Anselmi, Amedeo, Mansour, Alexandre, Para, Marylou, Mongardon, Nicolas, Porto, Alizée, Guihaire, Julien, Morgant, Marie-Catherine, Pozzi, Matteo, Cholley, Bernard, Falcoz, Pierre-Emmanuel, Gaudard, Philippe, Lebreton, Guillaume, Labaste, François, Barbanti, Claudio, Fouquet, Olivier, Chocron, Sidney, Mottard, Nicolas, Esvan, Maxime, Fougerou-Leurent, Claire, Flecher, Erwan, Vincentelli, André, Nesseler, Nicolas, Pierrot, Marc, Flicoteaux, Guillaume, Mauriat, Philippe, Ouattara, Alexandre, Roze, Hadrien, Huet, Olivier, Fischer, Marc-Olivier, Alessandri, Claire, Bellaïche, Raphel, Constant, Ophélie, Roux, Quentin, Ly, André, Meffert, Arnaud, Merle, Jean-Claude, Picard, Lucile, Skripkina, Elena, Folliguet, Thierry, Fiore, Antonio, d'Ostrevy, Nicolas, Morgan, Marie-Catherine, Guinot, Pierre-Grégoire, Nguyen, Maxime, Gaide-Chevronnay, Lucie, Terzi, Nicolas, Colin, Gwenhaël, Fabre, Olivier, Astaneh, Arash, Issard, Justin, Fadel, Elie, Fabre, Dominique, Girault, Antoine, Ion, Iolande, Menager, Jean Baptiste, Mitilian, Delphine, Mercier, Olaf, Stephan, François, Thes, Jacques, Jouan, Jerôme, Duburcq, Thibault, Loobuyck, Valentin, Moussa, Mouhammed, Mugnier, Agnes, Rousse, Natacha, Manganiello, Sabrina, Desebbe, Olivier, Fellahi, Jean-Luc, Henaine, Roland, Richard, Jean-Christophe, Riad, Zakaria, Guervilly, Christophe, Hraiech, Sami, Papazian, Laurent, Castanier, Matthias, Chanavaz, Charles, Cadoz, Cyril, Gette, Sebastien, Louis, Guillaume, Portocarrero, Erick, Brini, Kais, Bischoff, Nicolas, Levy, Bruno, Kimmoun, Antoine, Mattei, Mathieu, Perez, Pierre, Bourdiol, Alexandre, Hourmant, Yannick, Mahé, Pierre-Joachim, Rozec, Bertrand, Vourc’h, Mickaël, Aubert, Stéphane, Bazalgette, Florian, Roger, Claire, Jaquet, Pierre, Lortat-Jacob, Brice, Mordant, Pierre, Nataf, Patrick, Patrier, Juliette, Provenchere, Sophie, Roué, Morgan, Sonneville, Romain, Tran-Dinh, Alexy, Wicky, Paul-Henri, Al Zreibi, Charles, Guyonvarch, Yannis, Hamada, Sophie, Bertier, Astrid, Harrois, Anatole, Matiello, Jordi, Kerforne, Thomas, Lacroix, Corentin, Brechot, Nicolas, Combes, Alain, Schmidt, Matthieu, Chommeloux, Juliette, Constantin, Jean Michel, D’alessandro, Cosimo, Demondion, Pierre, Demoule, Alexandre, Dres, Martin, Fadel, Guillaume, Fartoukh, Muriel, Hekimian, Guillaume, Juvin, Charles, Leprince, Pascal, Levy, David, Luyt, Charles Edouard, Pineton de Chambrun, Marc, Schoell, Thibaut, Fillâtre, Pierre, Massart, Nicolas, Nicolas, Roxane, Jonas, Maud, Vidal, Charles, Allou, Nicolas, Muccio, Salvatore, Di Perna, Dario, Ruggieri, Vito-Giovanni, Mourvillier, Bruno, Bounader, Karl, Launey, Yoann, Lebouvier, Thomas, Parasido, Alessandro, Reizine, Florian, Seguin, Philippe, Besnier, Emmanuel, Carpentier, Dorothée, Clavier, Thomas, Olland, Anne, Villard, Marion, Bounes, Fanny, Minville, Vincent, Guillon, Antoine, Fedun, Yannick, Ross, James, Laboratoire Traitement du Signal et de l'Image (LTSI), Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Laboratoire de Recherche Vasculaire Translationnelle (LVTS (UMR_S_1148 / U1148)), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité)-Université Sorbonne Paris Nord, Institut Mondor de Recherche Biomédicale (IMRB), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), IMRB - PROTECT/'Pharmacologie et Technologies pour les Maladies Cardiovasculaires' [Créteil] (U955 Inserm - UPEC), Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12)-Institut National de la Santé et de la Recherche Médicale (INSERM)-IFR10-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Pôle des Cardiopathies Congénitales du Nouveau-Né à L'adulte - Centre Constitutif Cardiopathies Congénitales Complexes M3C, Groupe Hospitalier Paris Saint-Joseph, Hôpital Marie-Lannelongue, Inserm U999, Université Paris-Saclay, Research on Healthcare Performance (RESHAPE - Inserm U1290 - UCBL1), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de la Santé et de la Recherche Médicale (INSERM), Innovations thérapeutiques en hémostase = Innovative Therapies in Haemostasis (IThEM - U1140), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Paris Cité (UPCité), Centre recherche en CardioVasculaire et Nutrition = Center for CardioVascular and Nutrition research (C2VN), Aix Marseille Université (AMU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Sorbonne Université (SU)-Institut de Cardiométabolisme et Nutrition = Institute of Cardiometabolism and Nutrition [CHU Pitié Salpêtrière] (IHU ICAN), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Franco-czech Laboratory for clinical research on obesity, Charles University [Prague] (CU)-Institut National de la Santé et de la Recherche Médicale (INSERM), MitoVasc - Physiopathologie Cardiovasculaire et Mitochondriale (MITOVASC), Université d'Angers (UA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Nutrition, Métabolismes et Cancer (NuMeCan), and Université de Rennes (UR)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE)

Subjects
Heart Failure, [SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular system, VA-ECMO, [SDV.IB]Life Sciences [q-bio]/Bioengineering, Outcomes, Covid-19
Abstract

International audience; Objectives: The clinical profile and outcomes of patients with Covid-19 who require veno-arterial or veno-venous-arterial extracorporeal membrane oxygenation (VA-ECMO - VAV-ECMO) are poorly understood. We aimed to describe the characteristics and outcomes of these patients and to identify predictors of both favorable and unfavorable outcomes.Methods: ECMOSARS is a multicenter, prospective, nationwide French registry enrolling patients who require VV/VA-ECMO in the context of Covid-19 infection (652 patients at 41 centers). We focused on 47 patients supported with VA- or VAV-ECMO for refractory cardiogenic shock.Results: Median age was 49. 14% of patients had a prior diagnosis of heart failure. The most common etiologies of cardiogenic shock were acute pulmonary embolism (30%), myocarditis (28%), and acute coronary syndrome (4%). E-CPR (Extracorporeal Cardiopulmonary Resuscitation) occurred in 38%. In-hospital survival was 28% in the whole cohort, and 43% when E-CPR patients were excluded. ECMO cannulation was associated with significant improvements in pH and FiO2 on day one, but non-survivors showed significantly more severe acidosis and higher FiO2 than survivors at this point (p = 0.030 and p = 0.006). Other factors associated with death were greater age (p = 0.02), higher BMI (p = 0.03), E-CPR (p = 0.001), non-myocarditis etiology (p = 0.02), higher serum lactates (p = 0.004), epinephrine (but not noradrenaline) use before initiation of ECMO (p = 0.003), hemorrhagic complications (p = 0.001), greater transfusion requirements (p = 0.001), and more severe SAVE and SAFE scores (p = 0.01 and p = 0.03).Conclusions: We report the largest focused analysis of VA- and VAV-ECMO recipients in Covid-19. Although relatively rare, the need for temporary mechanical circulatory support in these patients is associated with poor prognosis. However, VA-ECMO remains a viable solution to rescue carefully selected patients. We identified factors associated with poor prognosis and suggest that E-CPR is not a reasonable indication for VA-ECMO in this population.

Published
2023

45. Sleeve lobectomy in patients with non-small-cell lung cancer: a report from the European Society of Thoracic Surgery database 2021

Author

Gonzalez, Michel, primary, Chriqui, Louis-Emmanuel, additional, Décaluwé, Herbert, additional, Aigner, Clemens, additional, Rényi-Vámos, Ferenc, additional, Opitz, Isabelle, additional, Furák, József, additional, Szanto, Zalan, additional, Brunelli, Alessandro, additional, and Falcoz, Pierre-Emmanuel, additional

Published
2022
Full Text
View/download PDF

46. Online Survey Evaluation of Three Years of European Society of Thoracic Surgeons Educational Webinars as Part of The E‐learning Platform

Author

Depypere, Lieven P., primary, Novoa, Nuria, additional, Daddi, Niccolò, additional, Assouad, Jalal, additional, Agrafiotis, Apostolos C., additional, Lauk, Olivia, additional, Decaluwé, Herbert, additional, Falcoz, Pierre Emmanuel, additional, Opitz, Isabelle, additional, Brunelli, Alessandro, additional, and Batirel, Hasan Fevzi, additional

Published
2022
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results